Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease
Stephan R. Targan, Brian G. Feagan, Séverine Vermeire, et al.
The American Journal of Gastroenterology (2016) Vol. 111, Iss. 11, pp. 1599-1607
Closed Access | Times Cited: 328

Showing 26-50 of 328 citing articles:

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations
Alexander Nast, Catherine Smith, Phyllis I. Spuls, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 35, Iss. 2, pp. 281-317
Open Access | Times Cited: 144
Role of the IL23/IL17 Pathway in Crohn’s Disease
H Schmitt, Markus F. Neurath, Raja Atreya
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 138
Cytokine-Mediated Crosstalk between Immune Cells and Epithelial Cells in the Gut
Mousumi Mahapatro, Lena Erkert, Christoph Becker
Cells (2021) Vol. 10, Iss. 1, pp. 111-111
Open Access | Times Cited: 114
Intestinal Stem Cells and Immune Cell Relationships: Potential Therapeutic Targets for Inflammatory Bowel Diseases
Qihang Hou, Jingxi Huang, Hammed Ayansola, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 108
Inflammatory Bowel Disease: A Review of Pre-Clinical Murine Models of Human Disease
Brunette Katsandegwaza, William Horsnell, Katherine A. Smith
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9344-9344
Open Access | Times Cited: 107
CD4 T-Cell Subsets and the Pathophysiology of Inflammatory Bowel Disease
Raquel Gómez-Bris, Ángela Saéz, Beatriz Herrero‐Fernández, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2696-2696
Open Access | Times Cited: 106
The role of Th17 cells in inflammatory bowel disease and the research progress
Lu Chen, Guangcong Ruan, Yi Cheng, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 87
Interleukin-23 in the Pathogenesis of Inflammatory Bowel Disease and Implications for Therapeutic Intervention
Gavin W. Sewell, Arthur Kaser
Journal of Crohn s and Colitis (2022) Vol. 16, Iss. Supplement_2, pp. ii3-ii19
Open Access | Times Cited: 79
Psoriatic Arthritis: Pathogenesis and Targeted Therapies
Ana Belén Azuaga, Julio Ramírez, Juan D. Cañete
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4901-4901
Open Access | Times Cited: 70
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Yuxiong Jiang, Youdong Chen, Qian Yu, et al.
BioDrugs (2023) Vol. 37, Iss. 1, pp. 35-55
Open Access | Times Cited: 56
The Promising Role of Polyphenols in Skin Disorders
Mohd Farhan
Molecules (2024) Vol. 29, Iss. 4, pp. 865-865
Open Access | Times Cited: 23
Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities
Iliyan D. Iliev, Ashwin N. Ananthakrishnan, Chun‐Jun Guo
Nature Reviews Microbiology (2025)
Closed Access | Times Cited: 2
Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease
Megan Hohenberger, Leah A. Cardwell, Elias Oussedik, et al.
Journal of Dermatological Treatment (2017) Vol. 29, Iss. 1, pp. 13-18
Closed Access | Times Cited: 150
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study
Brian G. Feagan, Julián Panés, Marc Ferrante, et al.
˜The œLancet. Gastroenterology & hepatology (2018) Vol. 3, Iss. 10, pp. 671-680
Open Access | Times Cited: 144
IL-17 in the immunopathogenesis of spondyloarthritis
Leonie S. Taams, Kathryn J. A. Steel, Ushani Srenathan, et al.
Nature Reviews Rheumatology (2018) Vol. 14, Iss. 8, pp. 453-466
Open Access | Times Cited: 127
Mucocutaneous IL-17 immunity in mice and humans: host defense vs. excessive inflammation
J Li, Jean‐Laurent Casanova, Anne Puel
Mucosal Immunology (2017) Vol. 11, Iss. 3, pp. 581-589
Open Access | Times Cited: 121
Dissecting the Heterogeneity in T-Cell Mediated Inflammation in IBD
Irma Tindemans, Maria E. Joosse, Janneke N. Samsom
Cells (2020) Vol. 9, Iss. 1, pp. 110-110
Open Access | Times Cited: 120
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Joshua S. Davis, David Ferreira, Emma Paige, et al.
Clinical Microbiology Reviews (2020) Vol. 33, Iss. 3
Open Access | Times Cited: 118
Safety of biologics in psoriasis
Masahiro Kamata, Yayoi Tada
The Journal of Dermatology (2017) Vol. 45, Iss. 3, pp. 279-286
Closed Access | Times Cited: 116
The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
Leonie C.S. De Vries, Manon E. Wildenberg, Wouter J. de Jonge, et al.
Journal of Crohn s and Colitis (2017) Vol. 11, Iss. 7, pp. 885-893
Open Access | Times Cited: 103
The current state of the art for biological therapies and new small molecules in inflammatory bowel disease
Sudarshan Paramsothy, Adam Rosenstein, Saurabh Mehandru, et al.
Mucosal Immunology (2018) Vol. 11, Iss. 6, pp. 1558-1570
Open Access | Times Cited: 100
The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study
John W. Frew, Kristina Navrazhina, David Grand, et al.
Journal of the American Academy of Dermatology (2020) Vol. 83, Iss. 5, pp. 1341-1348
Open Access | Times Cited: 99
Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders
Melinda Gooderham, Kim Papp, Charles Lynde
Journal of the European Academy of Dermatology and Venereology (2018) Vol. 32, Iss. 7, pp. 1111-1119
Open Access | Times Cited: 98
Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?
Stefan Siebert, Neal L. Millar, Iain B. McInnes
Annals of the Rheumatic Diseases (2018) Vol. 78, Iss. 8, pp. 1015-1018
Open Access | Times Cited: 91
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials
Kristian Reich, Craig L. Leonardi, Richard Langley, et al.
Journal of the American Academy of Dermatology (2016) Vol. 76, Iss. 3, pp. 441-448.e2
Open Access | Times Cited: 89

Scroll to top